NextCure, Inc. (NASDAQ:NXTC - Get Free Report) major shareholder Adar1 Capital Management, Llc purchased 3,662 shares of the stock in a transaction dated Friday, November 6th. The stock was acquired at an average cost of $5.10 per share, for a total transaction of $18,676.20. Following the transaction, the insider owned 737,956 shares of the company's stock, valued at approximately $3,763,575.60. This trade represents a 0.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Adar1 Capital Management, Llc also recently made the following trade(s):
- On Thursday, November 5th, Adar1 Capital Management, Llc purchased 1,024 shares of NextCure stock. The shares were acquired at an average price of $5.10 per share, for a total transaction of $5,222.40.
- On Tuesday, October 27th, Adar1 Capital Management, Llc purchased 3,553 shares of NextCure stock. The shares were acquired at an average price of $5.10 per share, for a total transaction of $18,120.30.
- On Monday, October 26th, Adar1 Capital Management, Llc acquired 1,672 shares of NextCure stock. The stock was acquired at an average cost of $5.03 per share, with a total value of $8,410.16.
- On Friday, October 23rd, Adar1 Capital Management, Llc acquired 5,626 shares of NextCure stock. The stock was acquired at an average cost of $4.83 per share, with a total value of $27,173.58.
NextCure Trading Up 17.6%
NextCure stock opened at $6.27 on Tuesday. NextCure, Inc. has a 1-year low of $1.55 and a 1-year high of $15.74. The firm has a market capitalization of $22.63 million, a price-to-earnings ratio of -0.72 and a beta of 1.22. The firm has a 50 day simple moving average of $6.06 and a 200 day simple moving average of $7.67.
Analysts Set New Price Targets
NXTC has been the subject of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating on shares of NextCure in a report on Thursday, August 13th. Wall Street Zen upgraded NextCure from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Finally, Weiss Ratings cut NextCure from a "sell (d-)" rating to a "sell (e+)" rating in a report on Monday, October 26th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $20.00.
Check Out Our Latest Stock Analysis on NextCure
Hedge Funds Weigh In On NextCure
An institutional investor recently raised its stake in NextCure stock. Renaissance Technologies LLC increased its position in shares of NextCure, Inc. (NASDAQ:NXTC - Free Report) by 80.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 60,534 shares of the company's stock after acquiring an additional 26,900 shares during the period. Renaissance Technologies LLC owned approximately 1.68% of NextCure worth $647,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 42.65% of the company's stock.
NextCure Company Profile
(
Get Free Report)
NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company's research is aimed at identifying and targeting biological mechanisms that suppress the immune system's ability to recognize and attack tumor cells.
NextCure's product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.
Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
